表紙
市場調查報告書
商品編碼
1028764

症候群多重診斷市場:Covid-19 影響、策略和趨勢:症候群(呼吸、膿毒症、胃腸道等)、位置、產品、國家預測:市場分析、執行指南和定制(2021 年)~2025 年)

Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Place, by Product and by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025

出版日期: | 出版商: Howe Sound Research | 英文 501 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

COVID 大流行預示著傳染病診斷新世界的到來。傳染病診斷正在發生變化,並將繼續發生變化。

市場上正在展示症候群測試。市場進入者報告了兩位數的增長。它有助於降低成本、改善治療效果並對抗抗菌素耐藥性。

本報告探討了症候群多重診斷市場,並按症候群、位置、產品、國家和進入市場的公司概況提供了市場概況以及趨勢。

目錄

第 1 章市場指南

  • COVID 影響的情況分析和概述
  • 高管和營銷人員指南
  • 投資分析師和管理顧問指南
  • 大公司的市場份額-表格和圖表

第 2 章市場的介紹和定義

  • 什麼是症候群多重測試?
  • 症候群檢測——診斷領域的一場悄然革命
    • 症候群測試
  • 市場定義
    • 多元市場規模
    • 貨幣
  • 調查方法
    • 作者
    • 來源
  • 前景:醫療保健、IVD 行業和 COVID-19 大流行
    • 全球醫療保健支出
    • 診斷費用
    • 保險對診斷的重要作用

第 3 章傳染病-病原體指南

  • 冠狀病毒
    • 嚴重急性呼吸系統綜合症 (SARS)
    • 中東呼吸症候群 (MERS)
    • COVID-19
  • HIV-人類免疫缺陷病毒 (AIDS)
    • 病毒學
    • 診斷
    • 檢驗
  • HBV-B 型肝炎
    • 病毒學
    • 機制
    • 診斷
    • 市場機會分析
  • HCV-C 型肝炎
    • 分類方法
    • 分子生物學
    • 複製
    • 基因型
    • 市場機會分析
  • 2.4HPV-人乳頭瘤病毒
    • 病毒學
    • 診斷
    • 市場機會分析
  • 流感
    • 病毒學
    • 檢驗
    • 市場機會分析
  • CTGC-衣原體/淋病
    • 淋病
    • 衣原體
    • 檢驗
    • 市場機會分析
  • 結核病
    • 分枝桿菌
    • 診斷
    • 流行病學
    • 分子診斷測試
    • 市場機會分析
  • MRSA-耐甲氧西林金黃色葡萄球菌
    • 診斷
    • FDA 批准的分子檢測
    • 市場機會分析
  • VRE-萬古黴素耐藥腸球菌
    • FDA 批准的 VRE 分子診斷測試
    • 市場機會分析

第 4 章行業概況

  • 行業參與者
    • IVD 供應商
    • 獨立實驗室:專業/難點領域
    • 獨立實驗室:國家/地區
    • 獨立實驗室:分析
    • 公共國家/地區研究所
    • 醫院實驗室
    • 從業者實驗室
    • 審計機構
  • 臨床檢測細分市場
    • 傳統的市場細分
    • 實驗室重點和細分
    • 症狀測試市場細分
  • 產業結構
    • 醫院檢查分享
    • 規模經濟
    • 從業者實驗室
    • 醫生和 POCT

第 5 章市場趨勢

  • 生長促進因素
    • 診斷速度
    • 症候群測試對成本的影響
    • 護理點的好處
    • 綜合測試、準確性和診斷風險
    • 1 次訪問
    • 改善結果
    • COVID-19 大流行的影響
  • 生長抑制因素
    • 低價
    • 管理/贖回
    • 減少傳染病
    • 健康危害
    • 通過經濟增長提高生活水平
    • 大流行性衰退的影響
  • 儀器儀表和自動化
    • 設備是市場份額的關鍵
    • 收縮器
    • 症候群測試會轉移到更大的設備上嗎?
  • 診斷技術的發展
    • Syndromictrends.com
    • 症候群與靶向檢測的比較
    • 多重範式轉變
    • 膿毒症檢測市場-症候群領導者
    • 一次就診與抗菌性
    • 症候群測試促進 POCT 的採用
    • PCR 的大未來

第 6 章症候群測試-最新進展

第 7 章主要症狀檢測公司簡介

第 8 章世界症候群多重診斷市場

  • 按國家/地區分列的全球市場概覽
    • Table-World Markets by Country
    • 圖表-按國家/地區劃分的世界市場
  • World Market-By Syndrome-概覽
    • Table-World Market-By 症候群
    • 圖表-世界市場-按症候群-標準/最後一年比較
    • 圖表-世界市場-按症候群-基年
    • 圖表-世界市場-按症候群-年末
    • 圖表-世界市場-按症候群-按年份額
    • Chart-World Marketplace-By Syndrome-Segment Growth
  • 世界市場-按位置-概覽
    • Table-World Markets-By Location
    • 圖表-世界市場-按位置-標準/最後一年比較
    • 圖表-世界市場-按位置-基準年
    • 圖表-世界市場-按地點-年末
    • 圖表-世界市場-按位置-按年份額
    • 圖表-世界市場-按位置-細分市場增長
  • 按產品分類的全球市場概覽
    • Table-World Market-By Product
    • 圖表-世界市場-按產品-標準/去年比較
    • 圖表-世界市場-按產品-基準年
    • 圖表-世界市場-按產品-年末
    • 圖表-世界市場-按產品-年份額
    • 圖表世界市場-按產品細分市場增長

第 9 章世界症候群多重市場-按症候群

  • 呼吸系統
  • 胃腸道
  • 腦膜炎/腦炎
  • 性傳播疾病
  • 其他

第 10 章世界症候群多市場-按位置

  • 醫院實驗室
  • 門診實驗室
  • 概念驗證
  • 其他

第 11 章全球症候群多重市場-副產品

  • 設備
  • 墨盒
  • 試劑
  • 其他

第 12 章附錄

目錄

OVERVIEW:

The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2025. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis & COVID Impact Overview
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 What are Syndromic Multiplex Tests?
  • 2.2 Syndromic Testing - the quiet revolution in diagnostics
    • 2.2.1 Syndromic Testing - more than Panels
  • 2.3 Market Definition
    • 2.3.1 Multiplex Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 The Coronavirus
    • 3.1.1 Severe acute respiratory syndrome (SARS)
    • 3.1.2 Middle East respiratory syndrome (MERS)
    • 3.1.3 COVID-19. The SARS CoV 2 Virus
      • 3.1.3.1 Signs and symptoms
      • 3.1.3.2 Transmission
      • 3.1.3.3 Diagnosis
      • 3.1.3.4 Prevention
      • 3.1.3.5 Management
      • 3.1.3.6 Prognosis
      • 3.1.3.7 New Strains and Subsequent Mutations
  • 3.3 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.3.1 Virology
      • 3.3.1.1 Classification
      • 3.3.1.2 Structure and genome
      • 3.3.1.3 Tropism
      • 3.3.1.4 Replication cycle
      • 3.3.1.5 Genetic variability
    • 3.3.2 Diagnosis
    • 3.3.3 Testing
      • 3.3.3.1 Antibody tests
      • 3.3.3.2 Point of Care Tests (POCT)
      • 3.3.3.3 Antigen Tests
      • 3.3.3.4 Nucleic acid-based tests (NAT)
      • 3.3.3.5 Other tests used in HIV treatment
  • 3.4 HBV - Hepatitis B
    • 3.4.1 Virology
      • 3.4.1.1 Genome
      • 3.4.1.2 Pathogenesis
      • 3.4.1.3 Hepatitis B virus replication
      • 3.4.1.4 Serotypes and genotypes
    • 3.4.2 Mechanisms
    • 3.4.3 Diagnosis
    • 3.4.4 Market Opportunity Analysis
  • 3.5 HCV - Hepatitis C
    • 3.5.1 Taxonomy
      • 3.5.1.1 Structure
      • 3.5.1.2 Genome
    • 3.5.2 Molecular biology
    • 3.5.3 Replication
    • 3.5.4 Genotypes
      • 3.5.4.1 Clinical importance
    • 3.5.5 Market Opportunity Analysis
  • 3.6 2.4 HPV - Human papillomavirus
    • 3.6.1 Virology
      • 3.6.1.1 E6/E7 proteins
      • 3.6.1.2 Role in cancer
      • 3.6.1.3 E2 research
      • 3.6.1.4 Latency period
      • 3.6.1.5 Clearance
    • 3.6.2 Diagnosis
      • 3.6.2.1 Cervical testing
      • 3.6.2.2 Oral testing
      • 3.6.2.3 Testing men
      • 3.6.2.4 Other testing
    • 3.6.3 Market Opportunity Analysis
  • 3.7 Influenza
    • 3.7.1 Virology
      • 3.7.1.1 Types of virus
      • 3.7.1.2 Influenzavirus A
      • 3.7.1.3 Influenzavirus B
      • 3.7.1.4 Influenzavirus C
      • 3.7.1.5 Structure, properties, and subtype nomenclature
      • 3.7.1.6 Replication
    • 3.7.2 Testing
      • 3.7.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.7.3 Market Opportunity Analysis
  • 3.8 CTGC - Chlamydia/Gonorhea
    • 3.8.1 Gonorrhea
      • 3.8.1.1 Diagnosis
      • 3.8.1.2 Screening
    • 3.8.2 Chlamydia
      • 3.8.2.1 Diagnosis
      • 3.8.2.2 Screening
    • 3.8.3 Testing
      • 3.8.3.1 Nucleic acid amplification tests (NAATs)
      • 3.8.3.2 Performance of NAAT Tests
    • 3.8.4 Market Opportunity Analysis
  • 3.9 Tuberculosis
    • 3.9.1 Mycobacteria
    • 3.9.2 Diagnosis
      • 3.9.2.1 Active tuberculosis
      • 3.9.2.2 Latent tuberculosis
    • 3.9.3 Epidemiology
    • 3.9.4 Molecular Diagnostic Tests
    • 3.9.5 Market Opportunity Analysis
  • 3.10 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.10.1 Diagnosis
    • 3.10.2 FDA Approved Molecular Tests
    • 3.10.3 Market Opportunity Analysis
  • 3.11 VRE - Vancomycin-resistant Enterococcus
    • 3.11.1 FDA Approved MDx Tests for VRE
    • 3.11.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Industry Participants
    • 4.1.1 IVD Supplier
    • 4.1.2 Independent lab specialized/esoteric
    • 4.1.3 Independent lab national/regional
    • 4.1.4 Independent lab analytical
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician lab
    • 4.1.8 Audit body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Speed of Diagnosis
    • 5.1.2 Effect of Syndromic Testing on Costs
    • 5.1.3 Point of Care Advantage
    • 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 5.1.5 Single Visits
    • 5.1.6 Improvement in Outcomes
    • 5.1.7 Impact of the COVID-19 Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Prices
    • 5.2.2 Administration/reimbursement
    • 5.2.3 Infectious Disease is Declining But...
    • 5.2.4 Wellness Hurts
    • 5.2.5 Economic Growth improves Living Standards
    • 5.2.6 Impact of the Pandemic Recession
  • 5.3 Instrumentation and Automation
    • 5.3.1 Instruments Key to Market Share
    • 5.3.2 The Shrinking Machine
    • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4 Diagnostic Technology Development
    • 5.4.1 Syndromictrends.com
    • 5.4.2 Comparing Syndrome and Targeted Testing
    • 5.4.3 The Multiplex Paradigm Shift
    • 5.4.4 The Sepsis Testing Market - Bellwether for Syndromics
    • 5.4.5 The Single Visit and AntiMicrobial Resistance
    • 5.4.6 Syndromics drives POCT adoption
    • 5.4.7 A Big Future for PCR?

6 Syndromic Testing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 QuantuMDx Developing Syndromic Panels for European Launch
  • 6.3 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
  • 6.4 QuantumDx Gets CE Mark for Rapid PoC PCR System
  • 6.5 Bio-Rad Laboratories, Seegene Partner for MDx Development
  • 6.6 Baebies to Expand Finder Platform
  • 6.7 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
  • 6.8 Binx Health Targeting Clinics, DTC & OTC With STI Tests
  • 6.9 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
  • 6.10 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
  • 6.11 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
  • 6.12 New Approach Involves Silicon-Based Test for Infectious Disease Screening
  • 6.13 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • 6.14 Qiagen sees NeuMoDx as Growth Vehicle
  • 6.15 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • 6.16 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • 6.17 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • 6.18 Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • 6.19 ChromaCode Raises Additional $10M
  • 6.20 COVID-19 Patients Need Syndromic Testing
  • 6.21 GenMark Diagnostics - New Respiratory Panel due in June
  • 6.22 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • 6.23 Exact Diagnostics launches respiratory panel control
  • 6.24 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • 6.25 Nanomix Receives CE Mark for Diagnostic
  • 6.26 Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • 6.27 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • 6.28 QIAGEN's New GI Panel Performance Assessed
  • 6.29 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • 6.30 Applied BioCode Obtains FDA Clearance
  • 6.31 Meridian Bioscience to Acquire GenePOC Inc
  • 6.32 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • 6.33 Qiagen gets FDA clearance for syndromic testing system
  • 6.34 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • 6.35 Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • 6.36 Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • 6.37 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • 6.38 QuantuMDx and Molbio announce MoU
  • 6.39 Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • 6.40 Mobidiag Inks European, Middle Eastern Distribution Deals
  • 6.41 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial

7 Profiles of Key Syndromic Testing Companies

  • 7.1 Abacus Diagnostica
  • 7.2 Abbott Diagnostics
  • 7.3 Accelerate Diagnostics
  • 7.4 Ador Diagnostics
  • 7.5 Akonni Biosystems
  • 7.6 Alveo Technologies
  • 7.7 Antelope Dx
  • 7.8 Applied BioCode
  • 7.9 Aus Diagnostics
  • 7.10 Baebies
  • 7.11 Beckman Coulter Diagnostics
  • 7.12 Becton, Dickinson and Company
  • 7.13 Binx Health
  • 7.14 Biocartis
  • 7.15 BioFire Diagnostics (bioMérieux)
  • 7.16 bioMérieux Diagnostics
  • 7.17 Bio-Rad Laboratories, Inc
  • 7.18 Bosch Healthcare Solutions GmbH
  • 7.19 Cepheid (Danaher)
  • 7.20 Credo Diagnostics Biomedical
  • 7.21 Cue Health
  • 7.22 Curetis N.V. / Curetis GmbH
  • 7.23 Diagenode Diagnostics
  • 7.24 Diasorin S.p.A
  • 7.25 Enzo Life Sciences, Inc
  • 7.26 Eurofins Scientific
  • 7.27 Fluxergy
  • 7.28 Fusion Genomics
  • 7.29 Genetic Signatures
  • 7.30 GenMark Dx (Roche)
  • 7.31 Hibergene Diagnostics
  • 7.32 Hologic
  • 7.33 Immunexpress
  • 7.34 Inflammatix
  • 7.35 Invetech
  • 7.36 Janssen Diagnostics
  • 7.37 Karius
  • 7.38 Lexagene
  • 7.39 LightDeck Diagnostics
  • 7.40 Lucira Health
  • 7.41 Luminex Corp
  • 7.42 Maxim Biomedical
  • 7.43 Meridian Bioscience
  • 7.44 Mesa Biotech (Thermo Fisher)
  • 7.45 Millipore Sigma
  • 7.46 Mobidiag (Hologic)
  • 7.47 Molbio Diagnostics
  • 7.48 Nanomix
  • 7.49 Novel Microdevices
  • 7.50 Operon
  • 7.51 Oxford Nanopore Technologies
  • 7.52 Panagene
  • 7.53 Perkin Elmer
  • 7.54 Primerdesign (Novacyt)
  • 7.55 Prominex
  • 7.56 Qiagen Gmbh
  • 7.57 Quantumdx
  • 7.58 Quidel
  • 7.59 Roche Molecular Diagnostics
  • 7.60 Saw Diagnostics
  • 7.61 Seegene
  • 7.62 Siemens Healthineers
  • 7.63 Sona Nanotech
  • 7.64 SpeeDx
  • 7.65 T2 Biosystems
  • 7.66 Talis Biomedical
  • 7.67 Thermo Fisher Scientific Inc
  • 7.68 Veramarx
  • 7.69 Visby Medical
  • 7.70 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Place - Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth
  • 8.4 Global Market by Product - Overview
    • 8.4.1 Table - Global Market by Product
    • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Product - Base Year
    • 8.4.4 Chart - Global Market by Product - End Year
    • 8.4.5 Chart - Global Market by Product - Share by Year
    • 8.4.6 Chart - Global Market by Product - Segments Growth

9 Global Syndromic Multiplex Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other Syndrome
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Infectious Disease Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other - by Country
    • 10.4.2 Chart - Other Place Growth

11 Global MDx Infectious Disease Markets - by Product

  • 11.1 Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 Cartridges
    • 11.2.1 Table Cartridges - by Country
    • 11.2.2 Chart - Cartridges Growth
  • 11.3 Reagents
    • 11.3.1 Table Reagents - by Country
    • 11.3.2 Chart - Reagents Growth
  • 11.4 Other Product
    • 11.4.1 Table Other Product - by Country
    • 11.4.2 Chart - Other Product Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Characteristics of Coronavirus Pandemic Infections
  • Table 3 COVID-19 Symptoms
  • Table 4 Classification of HIV Species
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 Influenza Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 Market Players by Type
  • Table 23 Clinical Laboratory Departments and Segments
  • Table 24 Laboratory Management Focus - Different Approaches
  • Table 25 Key Segmentation Variables Going Forward
  • Table 26 Possible Market Segments of Syndromic Multiplex Market
  • Table 27 Five Factors Driving Growth
  • Table 28 How SMT Improves Outcomes
  • Table 29 Four Factors Limiting Growth
  • Table 30 - Global Market by Region
  • Table 31 Global Market by Syndrome
  • Table 32 Global Market by Place
  • Table 33 Global Market by Product
  • Table 34 Respiratory by Country
  • Table 35 Gastrointestinal by Country
  • Table 36 Blood by Country
  • Table 37 Meningitis/Encephalitis by Country
  • Table 38 Sexually Transmitted Disease by Country
  • Table 39 Other by Country
  • Table 40 Hospital Lab by Country
  • Table 41 Outpatient Lab by Country
  • Table 42 Point of Care by Country
  • Table 43 Other by Country
  • Table 44 Instruments by Country
  • Table 45 Cartridges by Country
  • Table 46 Reagents by Country
  • Table 47 Other Product by Country
  • Table 48 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 The Global Healthcare Spending Picture
  • Figure 3 The Lab Test Pie
  • FIGURE 4 STRUCTURE OF CORONAVIRUSES
  • Figure 5 HIV Virion
  • Figure 6 Diagram of the HIV Replication Cycle
  • Figure 7 The Structure of the HBV Virus
  • Figure 8 Hepatitis B Replication
  • Figure 9 Structure of the HCV Virus
  • Figure 10 HCV Replication Cycle
  • Figure 11 Structure of the Influenza Virion
  • Figure 12 Influenza Replication
  • Figure 13 Scanning Electronmicrograph of Tuberculosis
  • Figure 14 Chart Death Rates and Infectious Disease Decline
  • Figure 15 Comparing Syndromic and Targeted Testing
  • Figure 16 The Multiplex Paradigm Shift
  • Figure 17 Global Market Share Chart
  • Figure 18 Global Market by Syndrome - Base vs. Final
  • Figure 19 Global Market by Syndrome Base Year
  • Figure 20 Global Market by Syndrome End Year
  • Figure 21 Syndrome Share by Year
  • Figure 22 Syndrome Segments Growth
  • Figure 23 Global Market by Place - Base vs. Final
  • Figure 24 Global Market by Place Base Year
  • Figure 25 Global Market by Place End Year
  • Figure 26 Place Share by Year
  • Figure 27 Place Segments Growth
  • Figure 28 Global Market by Product - Base vs. Final
  • Figure 29 Global Market by Product Base Year
  • Figure 30 Global Market by Product End Year
  • Figure 31 Product Share by Year
  • Figure 32 Product Segments Growth
  • Figure 33 Respiratory Growth
  • Figure 34 Gastrointestinal Diagnostics Growth
  • Figure 35 Blood Growth
  • Figure 36 Meningitis/Encephalitis Growth
  • Figure 37 Sexually Transmitted Disease Growth
  • Figure 38 Other Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 Point of Care Growth
  • Figure 42 Other Growth
  • Figure 43 Instruments Growth
  • Figure 44 Cartridges Growth
  • Figure 45 Reagents Growth
  • Figure 46 Other Product Growth